Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
S03 E17: Understanding MGUS, Smouldering Myeloma and Myeloma
MyeConversations by Myeloma Australia
18 minutes
2 years ago
S03 E17: Understanding MGUS, Smouldering Myeloma and Myeloma
In this episode of MyeConversations we talk to international guest Dr Shaji Kumar. Dr Kumar is an expert in plasma cell dyscrasia. We will learn more about the differences between MGUS, Smouldering Myeloma and Myeloma.
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
